Halozyme Therapeutics Inc. (NASDAQ: HALO) closed the day trading at $42.56 down -0.98% from the previous closing price of $42.98. In other words, the price has decreased by $-0.42 from its previous closing price. On the day, 716567 shares were traded. HALO stock price reached its highest trading level at $43.27 during the session, while it also had its lowest trading level at $42.42.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Ratios:
For a better understanding of HALO, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.95 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.19. For the most recent quarter (mrq), Quick Ratio is recorded 5.40 and its Current Ratio is at 6.60. In the meantime, Its Debt-to-Equity ratio is 9.91 whereas as Long-Term Debt/Eq ratio is at 9.91.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on July 24, 2023, initiated with a Buy rating and assigned the stock a target price of $61.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 31 when Torley Helen sold 10,000 shares for $42.82 per share. The transaction valued at 428,170 led to the insider holds 623,666 shares of the business.
Torley Helen sold 10,000 shares of HALO for $428,540 on Aug 30. The PRESIDENT AND CEO now owns 623,666 shares after completing the transaction at $42.85 per share. On Aug 29, another insider, Torley Helen, who serves as the PRESIDENT AND CEO of the company, sold 10,000 shares for $42.40 each. As a result, the insider received 424,020 and left with 623,666 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HALO now has a Market Capitalization of 5.61B and an Enterprise Value of 6.76B. As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 24.99, and their Forward P/E ratio for the next fiscal year is 11.50. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.96. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.18 while its Price-to-Book (P/B) ratio in mrq is 37.01. Its current Enterprise Value per Revenue stands at 8.74 whereas that against EBITDA is 17.41.
Stock Price History:
Over the past 52 weeks, HALO has reached a high of $59.46, while it has fallen to a 52-week low of $29.85. The 50-Day Moving Average of the stock is 40.54, while the 200-Day Moving Average is calculated to be 43.42.
Shares Statistics:
Over the past 3-months, HALO traded about 1.03M shares per day on average, while over the past 10 days, HALO traded about 698.28k shares per day. A total of 131.73M shares are outstanding, with a floating share count of 130.57M. Insiders hold about 0.80% of the company’s shares, while institutions hold 96.56% stake in the company. Shares short for HALO as of Aug 14, 2023 were 7.3M with a Short Ratio of 7.30M, compared to 7M on Jul 13, 2023. Therefore, it implies a Short% of Shares Outstanding of 5.53% and a Short% of Float of 6.55%.
Earnings Estimates
Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of $0.74 for the current quarter, with a high estimate of $0.78 and a low estimate of $0.71, while EPS last year was $0.74. The consensus estimate for the next quarter is $0.74, with high estimates of $0.77 and low estimates of $0.7.
Analysts are recommending an EPS of between $2.74 and $2.6 for the fiscal current year, implying an average EPS of $2.67. EPS for the following year is $3.7, with 6 analysts recommending between $4.58 and $2.73.
Revenue Estimates
8 analysts predict $226.83M in revenue for the current quarter. It ranges from a high estimate of $240.58M to a low estimate of $221M. As of the current estimate, Halozyme Therapeutics Inc.’s year-ago sales were $208.98M, an estimated increase of 8.50% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $230.82M, an increase of 27.20% over than the figure of $8.50% in the same quarter last year. There is a high estimate of $240M for the next quarter, whereas the lowest estimate is $220.26M.
A total of 10 analysts have provided revenue estimates for HALO’s current fiscal year. The highest revenue estimate was $846M, while the lowest revenue estimate was $833.33M, resulting in an average revenue estimate of $841.31M. In the same quarter a year ago, actual revenue was $660.12M, up 27.40% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $1.09B in the next fiscal year. The high estimate is $1.27B and the low estimate is $768M. The average revenue growth estimate for next year is up 29.40% from the average revenue estimate for this year.